Transcatheter Aortic Valve Replacement (TAVR)
Treatment for Non Rheumatic Calcific Aortic Valve Disease
Effectiveness
90%
Safety Score
45%
Clinical Trials
550
Participants
120K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate hemodynamic improvement, symptomatic relief within days to weeks
Treatment Duration
One-time procedure; valve durability 10-15+ years; initial procedure cost $30,000-$60,000.
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$1,500
Side Effect Mgmt:$1,000
Total Annual:$2,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
1.5
Comparison vs Surgical Aortic Valve Replacement (SAVR)
Cost Difference
+$5,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Transcatheter Aortic Valve Replacement (TAVR) Outcomes
for Non Rheumatic Calcific Aortic Valve Disease
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Remission Rate
+98%
Common Side Effects
Vascular complications
+7%
Stroke
+3%
New pacemaker implantation
+15%
Paravalvular leak (moderate/severe)
+4%
Acute kidney injury
+8%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov